Literature DB >> 7968937

Phencyclidine and (+)-MK-801-induced circling preference: correlation with monoamine levels in striatum of the rat brain.

S F Ali1, G D Newport, H S Bracha.   

Abstract

Phencyclidine (PCP; angel dust) is a drug of abuse known to produce a behavioral state in humans resembling schizophrenia/psychosis. PCP is a noncompetitive NMDA receptor antagonist and produces a variety of behaviors in rats including circling. The behavioral effects of other noncompetitive NMDA receptor antagonists such as (+)-MK-801 are still being elucidated. Here, adult female rats were dosed with PCP (10 mg/kg, IP), or (+)-MK-801 (0.1 mg/kg, IP) and circling preference was recorded for 2 h before sacrifice to determine monoamine levels by HPLC/EC. Animals injected with PCP or (+)-MK-801 showed a preference to turn to the left (65% and 72%, respectively). PCP and (+)-MK-801 also produced a significant increase of 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in whole striatum on both sides of the brain. Further dissection of the striatum into medioventral and dorsolateral regions revealed that HVA was increased bilaterally except in globus pallidus where we found significant increases in dopamine (DA), DOPAC, and HVA only on the left side after PCP and (+)-MK-801 administration. These data suggest that PCP and (+)-MK-801 produce a greater preference to turn left than right, a finding similar to that found in human psychosis. Furthermore, it is possible that this preference to turn toward the left hemispace is due to an asymmetry in dopamine function found in the globus pallidus after administration of PCP and similar drugs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7968937     DOI: 10.1016/0892-0362(94)90021-3

Source DB:  PubMed          Journal:  Neurotoxicol Teratol        ISSN: 0892-0362            Impact factor:   3.763


  8 in total

1.  Neonatal quinpirole treatment enhances locomotor activation and dopamine release in the nucleus accumbens core in response to amphetamine treatment in adulthood.

Authors:  Zackary A Cope; Kimberly N Huggins; A Brianna Sheppard; Daniel M Noel; David S Roane; Russell W Brown
Journal:  Synapse       Date:  2010-04       Impact factor: 2.562

2.  Dopamine-mediated MK-801-induced elevation in food-based extinction responding in rats and associated changes in region-specific phosphorylated ERK.

Authors:  Matthew R Holahan; Melanie J Clarke; Delaney D Hines
Journal:  Psychopharmacology (Berl)       Date:  2010-07-23       Impact factor: 4.530

3.  Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology.

Authors:  Evan J Kyzar; Christopher Collins; Siddharth Gaikwad; Jeremy Green; Andrew Roth; Louie Monnig; Mohamed El-Ounsi; Ari Davis; Andrew Freeman; Nicholas Capezio; Adam Michael Stewart; Allan V Kalueff
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-01-09       Impact factor: 5.067

4.  Animal Models of Psychosis: Current State and Future Directions.

Authors:  Alexandra D Forrest; Carlos A Coto; Steven J Siegel
Journal:  Curr Behav Neurosci Rep       Date:  2014-06-01

5.  Drug-induced circling preference in rats. Correlation with monoamine levels.

Authors:  S F Ali; K J Kordsmeier; B Gough
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

6.  Intra-accumbens injection of a dopamine aptamer abates MK-801-induced cognitive dysfunction in a model of schizophrenia.

Authors:  Matthew R Holahan; Dan Madularu; Erin M McConnell; Ryan Walsh; Maria C DeRosa
Journal:  PLoS One       Date:  2011-07-13       Impact factor: 3.240

7.  Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity.

Authors:  Erin W Tuplin; Matthew R Holahan
Journal:  Curr Neuropharmacol       Date:  2017-11-14       Impact factor: 7.363

8.  Quantifying free behaviour in an open field using k-motif approach.

Authors:  Marein Könings; Mark Blokpoel; Katarzyna Kapusta; Tom Claassen; Jan K Buitelaar; Jeffrey C Glennon; Natalia Z Bielczyk
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.